OmniAb, Inc.
Charles Berkman has extensive work experience in the legal field. Charles currently holds the position of Chief Legal Officer & Secretary at OmniAb, Inc. since November 2022. Prior to this, they served as Vice President, General Counsel & Secretary at Ligand Pharmaceuticals from November 2001 to November 2022. Before joining Ligand Pharmaceuticals, they worked as a Senior Associate at Baker & McKenzie from November 2000 to November 2001. Their career began as an Associate at Lyon & Lyon, where they worked from 1993 to 2000.
Charles Berkman attended Kirby Hall from 1980 to 1986. After completing high school, they went on to study Chemistry at The University of Texas at Austin from 1986 to 1990, earning their Bachelor of Science (BS) degree. Additionally, they pursued further education in Chemistry at The University of Texas School of Law from 1986 to 1993, where they earned another Bachelor of Science (BS) degree.
This person is not in any offices
OmniAb, Inc.
The OmniAb discovery platform provides pharmaceutical industry partners with access to diverse antibody repertoires and high-throughput screening technologies to enable discovery of next-generation therapeutics. At the heart of the OmniAb platform is the Biological Intelligence (BI) of our proprietary transgenic animals, including OmniRat,OmniChicken and OmniMouse, which have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur features unique structural attributes of cow antibodies for complex targets. OmniAb animals comprise the most diverse host systems available in the industry and they are optimally leveraged through computational antigen design and immunization methods, paired with high-throughput microfluidic-based single B cell screening and deep computational analysis of next-generation sequencing datasets to identify fully human antibodies with superior performance and developability characteristics. An established core competency focused on ion channels and transporters further differentiates our technology and creates opportunities to further leverage across modalities, including antibody-drug conjugates and others. The OmniAb suite of technologies and differentiating computational capabilities and BI features are combined to offer a highly efficient and customizable end-to-end solution for the growing discovery needs of the global pharmaceutical industry. For more information, please visit www.omniab.com.